CUPERTINO, Calif., Aug 24, 2001 /PRNewswire/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) press release regarding Chronogesic(TM) Phase II clinical trial data, you are invited to listen to its conference call that will be broadcast live over the Internet on Wednesday, September 5, 2001 at 8:30 a.m. EDT with Jim Brown, President and Chief […]
CUPERTINO, Calif., July 30 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2001. The company’s net loss attributable to common stockholders for the three months ended June 30, 2001 was $7.0 million or 15 cents per share (excluding a one-time, non-cash charge) compared to $5.2 million,
DURECT Corporation Reports Second Quarter 2001 Financial Results Read More »
CUPERTINO, Calif., Jul 19, 2001 /PRNewswire/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) second quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Monday, July 30, 2001 at 4:30 p.m. EDT with Jim Brown, President and Chief Executive Officer, Tom
CUPERTINO, Calif., Jul 6, 2001 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that its Board of Directors adopted a Stockholder Rights Plan. The Rights Plan is designed to protect and maximize the value of stockholders’ interest in DURECT Corporation, to enable all DURECT stockholders to realize the full value of their investment and to
Durect Corporation Adopts Stockholder Rights Plan Read More »
CUPERTINO, Calif., June 29 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today the preliminary results of its Phase II clinical trial for its lead product, a 3-month continuous infusion subcutaneous implant for the treatment of chronic pain. The product, previously referred to as DUROS sufentanil, has been given the product name Chronogesic(TM). The preliminary results
DURECT Announces Chronogesic Preliminary Clinical Results of Phase II Trial Read More »
CUPERTINO, Calif., Jun 25, 2001 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that it has filed a Special 510(k) pre-market notification with the FDA for its next generation ear delivery catheter. Like its predecessor IntraEAR(R) catheters, the Microdose Cath(TM) is intended for the site-directed delivery of fluids to the round window area of the
CUPERTINO, Calif., June 25 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that it has filed a Special 510(k) pre-market notification with the FDA for its next generation ear delivery catheter. Like its predecessor IntraEAR(R) catheters, the Microdose Cath(TM) is intended for the site-directed delivery of fluids to the round window area of the middle
CUPERTINO, Calif., May 24 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX – news) today announced that it has completed construction of a commercial manufacturing facility that is expected to meet DURECT’s production needs for Phase III clinical batches, FDA registration batches and commercial launch of DUROS sufentanil. The facility is designed to use advanced procedures to
DURECT Completes Construction of Commercial Manufacturing Facility Read More »
CUPERTINO, Calif., May 11 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that the company has completed the clinical portion of its Phase II clinical trial for the company’s lead product, DUROS sufentanil. The last patient visit was completed and data analysis and report writing are underway. Over 50 patients at 9 clinical centers completed
CUPERTINO, Calif., April 30 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended March 31, 2001. The company’s net loss attributable to common stockholders for the three months ended March 31, 2001 was $4.9 million or 11 cents per share, compared to $4.7 million, or 71 cents per share,
DURECT Corporation Reports First Quarter 2001 Financial Results Read More »
